Yahoo Finance • 3 months ago
We recently compiled a list of the 10 Best Undervalued UK Stocks To Buy Now.In this article, we are going to take a look at where GSK plc (LON:GSK) stands against the other undervalued UK stocks. The Economy of the United Kingdom Accordi... Full story
Yahoo Finance • 11 months ago
In this article, we discuss the 13 best get rich quick stocks to buy. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Get Rich Quick Stocks To Buy. There are many reasons for investors to be optimistic abo... Full story
Yahoo Finance • 11 months ago
Jon and Pete Najarian join forces to discuss and debate their favorite topics, including the hottest stock-specific news and sports! Continue reading... Full story
Yahoo Finance • 11 months ago
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights utili... Full story
Yahoo Finance • last year
CureVac N.V. (NASDAQ:CVAC) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Greetings and welcome to the CureVac Financial Results for Third Quarter and First Nine Months of 2023 Business Update. At this time, all participants... Full story
Yahoo Finance • last year
Key Insights The considerable ownership by private equity firms in CureVac indicates that they collectively have a greater say in management and business strategy A total of 3 investors have a majority stake in the company with 52% owners... Full story
Yahoo Finance • last year
Participants Alexander Zehnder; CEO, MD & Member of Management Board; CureVac N.V. Marcus Dalton Myriam Mendila; Chief Development Officer, MD & Member of the Management Board; CureVac N.V. Pierre Kemula; MD, CFO & Member of Management... Full story
Yahoo Finance • last year
COVID-19 Phase 2 clinical trial fully enrolled Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine First participant dosed in seasonal flu Phase 2 part of combined Phase 1/2 study Study compa... Full story
Yahoo Finance • last year
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a suc... Full story
Yahoo Finance • last year
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), tod... Full story
Yahoo Finance • 2 years ago
Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline CureVac is filing counterclaim in U.S. court under nine patents covering foun... Full story
Yahoo Finance • 2 years ago
In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US hav... Full story
Yahoo Finance • 2 years ago
A High Court battle between Pfizer Inc (NYSE: PFE), its partner BioNTech SE (NASDAQ: BNTX) locked in a dispute with the rival COVID-19 vaccine maker Moderna Inc (NASDAQ: MRNA) over patents for vaccine technology is set to be heard in Londo... Full story
Yahoo Finance • 2 years ago
CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise. UBS analyst Eliana Merle upgraded the shares (ticker: CVAC) to Buy from Neutral and raised her 1... Full story
Yahoo Finance • 2 years ago
Moderna Inc. (Nasdaq: MRNA) is considering hiking the price of its Covid-19 vaccine up by up to 400%. Continue reading... Full story
Yahoo Finance • 2 years ago
Shares of CureVac (NASDAQ: CVAC) rose as much as 19.1% on Tuesday. Despite the rise, CureVac is down more than 59% over the past year, though it is now up more than 61% over the past three months. Investors continued to flock to the health... Full story
Yahoo Finance • 2 years ago
Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 9, 2023 / Cur... Full story
Yahoo Finance • 2 years ago
CureVac shares rocketed 26% in premarket trade as the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to advance to the next stage of clinical testing. CureVac is... Full story
Yahoo Finance • 2 years ago
(Adds further comment by companies) By Ludwig Burger FRANKFURT, July 26 (Reuters) - COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking... Full story
Yahoo Finance • 2 years ago
BERLIN, July 6 (Reuters) - BioNTech is looking into taking legal steps against CureVac after the latter filed a patent lawsuit against it over its use of mRNA technology, BioNTech said on Wednesday, confirming a report by daily Welt. "We... Full story